Guided Therapeutics (GTHP) Preferred Stock Liabilities (2013 - 2021)

Guided Therapeutics has disclosed Preferred Stock Liabilities across 8 years of filings, most recently posting $50000.0 for Q2 2021.

• In Q2 2021, Preferred Stock Liabilities changed N/A year-over-year to $50000.0; the TTM figure through Jun 2021 stood at $50000.0 (changed N/A YoY), while the FY2019 annual figure was $105000.0, changed 0.0% from the prior year.
• Preferred Stock Liabilities came in at $50000.0 for Q2 2021 at Guided Therapeutics, down from $125000.0 in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $701000.0 in Q1 2017 to a low of $50000.0 in Q2 2021.
• Average Preferred Stock Liabilities over 4 years is $306000.0, with a median of $125000.0 recorded in 2021.
• Year-over-year, Preferred Stock Liabilities tumbled 70.42% in 2018 and changed 0.0% in 2019.
• Over 4 years, Preferred Stock Liabilities stood at $355000.0 in 2017, then plunged by 70.42% to $105000.0 in 2018, then changed by 0.0% to $105000.0 in 2019, then tumbled by 52.38% to $50000.0 in 2021.
• Per Business Quant data, the three most recent Preferred Stock Liabilities figures were $50000.0 in Q2 2021, $125000.0 in Q1 2021, and $105000.0 in Q4 2019.